1. Home
  2. TNXP vs ANGI Comparison

TNXP vs ANGI Comparison

Compare TNXP & ANGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.32

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$4.98

Market Cap

180.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
ANGI
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
180.9M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
TNXP
ANGI
Price
$13.32
$4.98
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$17.00
AVG Volume (30 Days)
486.9K
871.9K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
1242.86
EPS
N/A
N/A
Revenue
$13,107,000.00
$736,386,000.00
Revenue This Year
$558.11
$3.25
Revenue Next Year
$38.29
$3.76
P/E Ratio
N/A
N/A
Revenue Growth
29.85
47.60
52 Week Low
$9.40
$4.26
52 Week High
$29.19
$18.70

Technical Indicators

Market Signals
Indicator
TNXP
ANGI
Relative Strength Index (RSI) 57.01 49.86
Support Level $11.98 $4.74
Resistance Level $13.36 $6.52
Average True Range (ATR) 0.71 0.30
MACD 0.04 0.06
Stochastic Oscillator 52.17 69.40

Price Performance

Historical Comparison
TNXP
ANGI

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

Share on Social Networks: